Types of Headaches

Headache Classifications and Clinical Assessment

The International Classification of Headache Disorders (ICHD-3) categorizes headaches into Primary (the headache is the disease) and Secondary (symptom of underlying pathology). For clinicians, differentiating between benign etiologies and life-threatening conditions like subarachnoid hemorrhage is essential. This guide outlines the pathophysiology, diagnostic criteria, and management protocols for major headache disorders.

Assessment requires structured history taking. For case analysis support, our nursing case study services provide diagnostic reasoning frameworks.

Primary Headache Disorders

These disorders lack an exogenous cause. The brain parenchyma is insensitive to pain; symptoms arise from the meninges, blood vessels, and pericranial muscles.

Tension-Type Headache (TTH)

Presentation: Bilateral, pressing/tightening (“band-like”) quality. Mild to moderate intensity. Not aggravated by physical activity. No vomiting; rare photophobia.
Management: Analgesics (NSAIDs, Acetaminophen).

Migraine

Presentation: Unilateral, pulsating quality. Moderate to severe intensity. Aggravated by activity. Associated with nausea, vomiting, photophobia, and phonophobia.
Phases:
1. Prodrome: Mood changes, cravings (hours/days before).
2. Aura: Neurological deficits (visual scintillations, sensory paresthesia) lasting 5-60 mins.
3. Attack: Headache phase (4-72 hours).
4. Postdrome: Fatigue, cognitive dulling.

Cluster Headache

A Trigeminal Autonomic Cephalalgia (TAC).
Presentation: Strictly unilateral, severe orbital/supraorbital/temporal pain. Attacks last 15-180 mins and occur in frequencies from 1 every other day to 8 per day.
Autonomic Signs: Ipsilateral conjunctival injection, lacrimation, nasal congestion, eyelid edema, ptosis, miosis.

Pathophysiology Mechanisms

Understanding the mechanism aids pharmacological selection.

Trigeminovascular System

Migraine involves activation of the Trigeminal Nerve (CN V). Stimulation releases vasoactive neuropeptides, specifically Calcitonin Gene-Related Peptide (CGRP) and Substance P. These cause vasodilation of intracranial blood vessels, plasma protein extravasation, and mast cell degranulation (neurogenic inflammation).

Secondary Headache Disorders

Headaches caused by exogenous factors or systemic disease.

Medication Overuse Headache (MOH)

Occurs in patients with pre-existing primary headache who overuse acute medication (>10-15 days/month). Characterized by worsening headache frequency despite treatment. Management involves withdrawal of the offending agent.

Giant Cell Arteritis (Temporal Arteritis)

Vasculitis affecting large/medium arteries.
Presentation: Age >50, new headache, temporal artery tenderness, jaw claudication.
Risk: Permanent blindness.
Diagnostic: Elevated ESR/CRP; temporal artery biopsy.

Idiopathic Intracranial Hypertension (IIH)

Raised intracranial pressure without a mass.
Presentation: Obese females of childbearing age. Headache, transient visual obscurations, pulsatile tinnitus.
Sign: Papilledema.

Diagnostic Assessment

History (SOCRATES): Site, Onset, Character, Radiation, Associations, Time, Exacerbating/Relieving factors, Severity.

Red Flags (SNOOP Criteria)

Imaging (CT/MRI) is indicated if red flags are present:
Systemic symptoms (fever, weight loss).
Neurologic signs (confusion, weakness).
Onset (sudden, thunderclap).
Older age (>50).
Pattern change (progressive, positional).

Pharmacological Management

Treatment is divided into acute (abortive) and preventive (prophylactic).

Abortive Therapy

Used during an attack.
NSAIDs: Ibuprofen, Naproxen (inhibit COX enzymes).
Triptans: Sumatriptan (5-HT1B/1D agonists). Induce vasoconstriction and inhibit CGRP release. Contraindicated in ischemic heart disease.

Prophylactic Therapy

Used to reduce frequency.
Beta-Blockers: Propranolol.
Antiepileptics: Topiramate, Valproate.
CGRP Antagonists: Erenumab (monoclonal antibody).

FAQs: Headache Classifications

Conclusion

Headaches vary from benign tension types to life-threatening hemorrhages. Classification using ICHD-3 criteria facilitates effective treatment. Recognizing SNOOP red flags ensures timely intervention for secondary pathologies.